<Hopefully AXGT works out for you. There was a lot of enthusiasm three years ago about the drug it bought from Glaxo for Alzheimer's (interpidine) along with would-be pimavanserin competitor nelotanserin. Both drugs flopped in the clinic. AXGT's stock fell 70%, and the company ended up doing an 1-for-8 reverse split.>
And thus the opportunity.
AXGT is a totally different company today, and David Hung is no longer there. Current CEO seems really sharp in the gene therapy arena, and they did a nice deal with Oxford Biomedica.
I followed the nelotanserin debacle, and thought that the ACAD drug was better. I have a lot of confidence in the ACAD, and in Esq. Davis.